Menu Search Facebook Twitter
Search Close
  • Capital Coahuila
  • Capital Hidalgo
  • Capital Jalisco
  • Capital Morelos
  • Capital Oaxaca
  • Capital Puebla
  • Capital Quintana Roo
  • Capital Querétaro
  • Capital Veracruz
  • Capital México
  • Capital Michoacán
  • Capital Mujer
  • Reporte Índigo
  • Estadio Deportes
  • The News
  • Efekto
  • Diario DF
  • Capital Edo. de Méx.
  • Green TV
  • Revista Cambio
Radio Capital
Pirata FM
Capital Máxima
Capital FM
Facebook Twitter
X Welcome! Subscribe to our newsletter and receive news, data, statistical and exclusive promotions for subscribers

Mylan Shares Languish at Low Valuation as EpiPen Congressional Hearing Nears

Teva Pharmaceutical Industries hopes to start selling an EpiPen-like device by 2018

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. Aug. 24, 2016, photo: Reuters/Jim Bourg
By The News Whatsapp Twitter Facebook Share
1 year ago

NEW YORK – Shares of Mylan NV are trading at historically low valuations as the company’s chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment.

The stock is trading at 7.5 times estimated earnings for the next 12 months, holding near its lowest in at least 30 years and well below its five-year average of 11 times, according to Thomson Reuters Datastream.

Since late August, when the EpiPen price increases came into the spotlight, Mylan shares have fallen about 15 percent. For the year, they are off about 23 percent, against a nearly 4 percent decline for the NYSE Arca Pharmaceutical index, a broad gauge of large and small drugmakers.

A test for the shares looms on Wednesday, when Mylan CEO Heather Bresch testifies before the U.S. House of Representatives Oversight Committee over price increases of EpiPen, an auto-injector of allergy medicine.

The hearing will come the day after West Virginia disclosed an investigation into whether Mylan violated antitrust laws or defrauded the state’s Medicaid program. A probe into EpiPen pricing by a U.S. Senate subcommittee was also announced on Sept. 7.

The stock “is just not working because of the overhang from all the headline stuff on EpiPen,” said Guggenheim Securities analyst Louise Chen, who rates the shares “neutral”.

One concern among analysts is how fallout over EpiPen pricing will affect Mylan’s roughly $1 billion in annual sales of the device.

Mylan said last month that it would introduce the first generic version of EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries, which hopes to start selling an EpiPen-like device by 2018.

Chen also said investors were unsure of the benefits from Mylan’s recently completed $7 billion acquisition of Swedish drugmaker Meda, which some had deemed expensive.

Deutsche Bank analyst Gregg Gilbert stuck to his “buy” rating on Mylan stock earlier this month, noting its valuation.

But in a research note, Gilbert cautioned: “Investors will have little patience if execution falters on the base business and/or the newly acquired Meda business.


Comments Whatsapp Twitter Facebook Share
More From The News
Latest News

Despite doping scandals, Olympic fever g ...

3 days ago

UAEM consolidates academic and scientifi ...

4 days ago
Latest News

Japan public TV sends mistaken North Kor ...

4 days ago
Latest News

Tillerson warns military action on NK un ...

4 days ago
Most Popular

Calzada Rovirosa: Mexico and Canada are ...

By The News

Obama: 'Absolutist' View Won't Solve Enc ...

By The News

Rouhani Says Can Provide Pakistan Gas Th ...

By The News

Orders For Lower-priced Tesla Reach 276, ...

By The News

Guajardo: A U.S. Anti-Trade Shift Would ...

By The News